Enzerna
Morrisville
About Enzerna
Enzerna Biosciences solution is to destroy the toxic RNA molecule that is the root cause of nucleotide expansion disorders using Artificial Site-Specific RNA Endonucleases (ASREs). ASREs are rationally designed proteins, that when expressed in cells, can target the expanded repeat array and destroy the disease-causing RNA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $250.0K
- Last round: Debt Financing (Nov 2022)
- Website: enzerna.com
- Phone: + 1 919 307 6468
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/enzerna-109444 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.